Context The optimal treatment for men with high-risk localized or locally advanced prostate
cancer (PCa) remains unknown. Objective To perform a systematic review of the existing …

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not
necessarily lead to clinically apparent progressive disease. To aid in prognostication, the …

Nearly 15% of individuals with localized prostate cancer are identified as high risk for
recurrence and progression of the disease, which is why the correct staging is vital for the …

Background Apalutamide plus androgen deprivation therapy (ADT) significantly improved
metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen …

Simple Summary Most men with prostate cancer will live as long as those who do not have
prostate cancer. However, some men will die early of their disease due to a particular type of …

The development of targeted therapies increases treatment options for metastatic castration
resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and …

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and
the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is …

PURPOSE To characterize the relationship between Decipher genomic classifier scores and
prostate-specific membrane antigen (PSMA) positron emission tomography/computed …

Simple Summary For prostate cancer patient, information on risk of long-term cancer-specific
and other-cause mortality is essential to avoid over-and undertreatment. Patient stratification …

Background Nutrition and physical activity are associated with prostate cancer recurrence
and mortality. Few randomized controlled trials (RCT) have examined the effects of long …